Skip to main content
Top
Published in: Diabetologia 11/2014

01-11-2014 | Review

Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations

Authors: Elisabetta Patorno, Amanda R. Patrick, Elizabeth M. Garry, Sebastian Schneeweiss, Victoria G. Gillet, Dorothee B. Bartels, Elvira Masso-Gonzalez, John D. Seeger

Published in: Diabetologia | Issue 11/2014

Login to get access

Abstract

Background

Recent years have witnessed a growing body of observational literature on the association between glucose-lowering treatments and cardiovascular disease. However, many of the studies are based on designs or analyses that inadequately address the methodological challenges involved.

Methods

We reviewed recent observational literature on the association between glucose-lowering medications and cardiovascular outcomes and assessed the design and analysis methods used, with a focus on their ability to address specific methodological challenges. We describe and illustrate these methodological issues and their impact on observed associations, providing examples from the reviewed literature. We suggest approaches that may be employed to manage these methodological challenges.

Results

From the evaluation of 81 publications of observational investigations assessing the association between glucose-lowering treatments and cardiovascular outcomes, we identified the following methodological challenges: 1) handling of temporality in administrative databases; 2) handling of risks that vary with time and treatment duration; 3) definitions of the exposure risk window; 4) handling of exposures that change over time; and 5) handling of confounding by indication. Most of these methodological challenges may be suitably addressed through application of appropriate methods.

Conclusions/interpretation

Observational research plays an increasingly important role in the evaluation of the clinical effects of diabetes treatment. Implementation of appropriate research methods holds the promise of reducing the potential for spurious findings and the risk that the spurious findings will mislead the medical community about risks and benefits of diabetes medications.
Appendix
Available only for authorised users
Literature
1.
go back to reference Arana A, Rivero E, Egberts TCG (2004) What do we show and who does so? An analysis of the abstracts presented at the 19th ICPE. Pharmacoepidemiol Drug Saf 13:S330–S331 Arana A, Rivero E, Egberts TCG (2004) What do we show and who does so? An analysis of the abstracts presented at the 19th ICPE. Pharmacoepidemiol Drug Saf 13:S330–S331
2.
go back to reference Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58:323–337PubMed Schneeweiss S, Avorn J (2005) A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 58:323–337PubMed
3.
go back to reference Schneeweiss S (2010) A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 19:858–868PubMedPubMedCentral Schneeweiss S (2010) A basic study design for expedited safety signal evaluation based on electronic healthcare data. Pharmacoepidemiol Drug Saf 19:858–868PubMedPubMedCentral
4.
go back to reference Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167:492–499PubMed Suissa S (2008) Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 167:492–499PubMed
5.
go back to reference Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345–2351PubMed Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA (2005) Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28:2345–2351PubMed
6.
go back to reference Johnson JA, Simpson SH, Toth EL, Majumdar SR (2005) Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497–502PubMed Johnson JA, Simpson SH, Toth EL, Majumdar SR (2005) Reduced cardiovascular morbidity and mortality associated with metformin use in subjects with type 2 diabetes. Diabet Med 22:497–502PubMed
7.
go back to reference Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A (2007) The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 50:32–36PubMed Aguilar D, Bozkurt B, Pritchett A, Petersen NJ, Deswal A (2007) The impact of thiazolidinedione use on outcomes in ambulatory patients with diabetes mellitus and heart failure. J Am Coll Cardiol 50:32–36PubMed
8.
go back to reference Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L (2008) Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29:177–184PubMed Anselmino M, Ohrvik J, Malmberg K, Standl E, Ryden L (2008) Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart. Eur Heart J 29:177–184PubMed
9.
go back to reference Khalangot M, Tronko M, Kravchenko V, Kovtun V (2009) Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 86:247–253PubMed Khalangot M, Tronko M, Kravchenko V, Kovtun V (2009) Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabetes Res Clin Pract 86:247–253PubMed
10.
go back to reference Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW (2009) Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf 32:675–690PubMed Hsiao FY, Huang WF, Wen YW, Chen PF, Kuo KN, Tsai YW (2009) Thiazolidinediones and cardiovascular events in patients with type 2 diabetes mellitus: a retrospective cohort study of over 473,000 patients using the National Health Insurance database in Taiwan. Drug Saf 32:675–690PubMed
11.
go back to reference Hsiao FY, Tsai YW, Wen YW et al (2010) Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf 19:786–791PubMed Hsiao FY, Tsai YW, Wen YW et al (2010) Relationship between cumulative dose of thiazolidinediones and clinical outcomes in type 2 diabetic patients with history of heart failure: a population-based cohort study in Taiwan. Pharmacoepidemiol Drug Saf 19:786–791PubMed
12.
go back to reference Corrao G, Romio SA, Zambon A, Merlino L, Bosi E, Scavini M (2011) Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur J Clin Pharmacol 67:289–299PubMed Corrao G, Romio SA, Zambon A, Merlino L, Bosi E, Scavini M (2011) Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy. Eur J Clin Pharmacol 67:289–299PubMed
13.
go back to reference Loebstein R, Dushinat M, Vesterman-Landes J et al (2011) Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol 51:173–180PubMed Loebstein R, Dushinat M, Vesterman-Landes J et al (2011) Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes. J Clin Pharmacol 51:173–180PubMed
14.
go back to reference Yeh HT, Hsieh CF, Tsai YW, Huang WF (2012) Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan. Clin Ther 34:885–893PubMed Yeh HT, Hsieh CF, Tsai YW, Huang WF (2012) Effects of thiazolidinediones on cardiovascular events in patients with type 2 diabetes mellitus after drug-eluting stent implantation: a retrospective cohort study using the national health insurance database in Taiwan. Clin Ther 34:885–893PubMed
15.
go back to reference Chao TF, Leu HB, Huang CC et al (2012) Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 156:199–202PubMed Chao TF, Leu HB, Huang CC et al (2012) Thiazolidinediones can prevent new onset atrial fibrillation in patients with non-insulin dependent diabetes. Int J Cardiol 156:199–202PubMed
16.
go back to reference Olsson J, Lindberg G, Gottsater M et al (2000) Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558–560PubMed Olsson J, Lindberg G, Gottsater M et al (2000) Increased mortality in type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43:558–560PubMed
17.
go back to reference Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244–2248PubMed Johnson JA, Majumdar SR, Simpson SH, Toth EL (2002) Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 25:2244–2248PubMed
18.
go back to reference Evans JM, Doney AS, AlZadjali MA et al (2010) Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 106:1006–1010PubMed Evans JM, Doney AS, AlZadjali MA et al (2010) Effect of metformin on mortality in patients with heart failure and type 2 diabetes mellitus. Am J Cardiol 106:1006–1010PubMed
19.
go back to reference Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA (2010) Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 12:47–53PubMed Gamble JM, Simpson SH, Eurich DT, Majumdar SR, Johnson JA (2010) Insulin use and increased risk of mortality in type 2 diabetes: a cohort study. Diabetes Obes Metab 12:47–53PubMed
20.
go back to reference Chou CC, Chen WL, Kao TW, Chang YW, Loh CH, Wang CC (2011) Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Clin Ther 33:1904–1913PubMed Chou CC, Chen WL, Kao TW, Chang YW, Loh CH, Wang CC (2011) Incidence of cardiovascular events in which 2 thiazolidinediones are used as add-on treatments for type 2 diabetes mellitus in a Taiwanese population. Clin Ther 33:1904–1913PubMed
21.
go back to reference Maru S, Koch GG, Stender M et al (2005) Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 28:20–26PubMed Maru S, Koch GG, Stender M et al (2005) Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the U.K. primary care setting. Diabetes Care 28:20–26PubMed
22.
go back to reference Engel-Nitz NM, Martin S, Sun P, Buesching D, Fonseca V (2008) Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clin Pract 81:97–104PubMed Engel-Nitz NM, Martin S, Sun P, Buesching D, Fonseca V (2008) Cardiovascular events and insulin therapy: a retrospective cohort analysis. Diabetes Res Clin Pract 81:97–104PubMed
23.
go back to reference Toprani A, Fonseca V (2011) Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab 13:276–280PubMed Toprani A, Fonseca V (2011) Thiazolidinediones and congestive heart failure in veterans with type 2 diabetes. Diabetes Obes Metab 13:276–280PubMed
24.
go back to reference Choy-Shan A, Zinn A, Shah B et al (2012) Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease. Coron Artery Dis 23:354–358PubMed Choy-Shan A, Zinn A, Shah B et al (2012) Effect of rosiglitazone on survival in patients with diabetes mellitus treated for coronary artery disease. Coron Artery Dis 23:354–358PubMed
25.
go back to reference Margolis DJ, Hoffstad O, Strom BL (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753–759PubMedPubMedCentral Margolis DJ, Hoffstad O, Strom BL (2008) Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 17:753–759PubMedPubMedCentral
26.
go back to reference Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB (2005) The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21:51–57PubMed Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB (2005) The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21:51–57PubMed
27.
go back to reference Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT (2004) Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 26:1400–1410PubMed Rajagopalan R, Rosenson RS, Fernandes AW, Khan M, Murray FT (2004) Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis. Clin Ther 26:1400–1410PubMed
28.
go back to reference Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM (2005) Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 22:986–993PubMedPubMedCentral Karter AJ, Ahmed AT, Liu J, Moffet HH, Parker MM (2005) Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabet Med 22:986–993PubMedPubMedCentral
29.
go back to reference Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 16:1065–1071PubMed Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S (2007) A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 16:1065–1071PubMed
30.
go back to reference Rhoads GG, Kosiborod M, Nesto RW et al (2009) Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 104:910–916PubMed Rhoads GG, Kosiborod M, Nesto RW et al (2009) Comparison of incidence of acute myocardial infarction in patients with type 2 diabetes mellitus following initiation of neutral protamine Hagedorn insulin versus insulin glargine. Am J Cardiol 104:910–916PubMed
31.
go back to reference Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ (2012) What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 97:4605–4612PubMed Morgan CL, Poole CD, Evans M, Barnett AH, Jenkins-Jones S, Currie CJ (2012) What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes. J Clin Endocrinol Metab 97:4605–4612PubMed
32.
go back to reference Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K (2009) The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther 31:2665–2677PubMed Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K (2009) The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. Clin Ther 31:2665–2677PubMed
33.
go back to reference Koro CE, Bowlin SJ, Weiss SR (2005) Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf 14:697–703PubMed Koro CE, Bowlin SJ, Weiss SR (2005) Antidiabetic therapy and the risk of heart failure in type 2 diabetic patients: an independent effect or confounding by indication. Pharmacoepidemiol Drug Saf 14:697–703PubMed
34.
go back to reference Horsdal HT, Sondergaard F, Johnsen SP, Rungby J (2011) Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. Pharmacoepidemiol Drug Saf 20:331–337PubMed Horsdal HT, Sondergaard F, Johnsen SP, Rungby J (2011) Antidiabetic treatments and risk of hospitalisation with myocardial infarction: a nationwide case-control study. Pharmacoepidemiol Drug Saf 20:331–337PubMed
35.
go back to reference Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL (2010) Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 3:538–545PubMed Wertz DA, Chang CL, Sarawate CA, Willey VJ, Cziraky MJ, Bohn RL (2010) Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population. Circ Cardiovasc Qual Outcomes 3:538–545PubMed
36.
go back to reference Kress S, Kostev K, Dippel FW, Giani G, Rathmann W (2012) Micro- and macrovascular outcomes in type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis. Int J Clin Pharmacol Ther 50:821–829PubMed Kress S, Kostev K, Dippel FW, Giani G, Rathmann W (2012) Micro- and macrovascular outcomes in type 2 diabetic patients treated with insulin glulisine or human regular insulin: a retrospective database analysis. Int J Clin Pharmacol Ther 50:821–829PubMed
37.
go back to reference McAlister FA, Eurich DT, Majumdar SR, Johnson JA (2008) The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 10:703–708PubMed McAlister FA, Eurich DT, Majumdar SR, Johnson JA (2008) The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 10:703–708PubMed
38.
go back to reference Marceille JR, Goins JA, Soni R, Biery JC, Lee TA (2004) Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 24:1317–1322PubMed Marceille JR, Goins JA, Soni R, Biery JC, Lee TA (2004) Chronic heart failure-related interventions after starting rosiglitazone in patients receiving insulin. Pharmacotherapy 24:1317–1322PubMed
39.
go back to reference Rothman KJ, Greenland S (1998) Modern epidemiology, 2nd edn. Lippincott-Raven, Philadelphia Rothman KJ, Greenland S (1998) Modern epidemiology, 2nd edn. Lippincott-Raven, Philadelphia
40.
go back to reference Schisterman EF, Cole SR, Platt RW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20:488–495PubMedPubMedCentral Schisterman EF, Cole SR, Platt RW (2009) Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology 20:488–495PubMedPubMedCentral
41.
go back to reference Greenland S (2003) Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology 14:300–306PubMed Greenland S (2003) Quantifying biases in causal models: classical confounding vs collider-stratification bias. Epidemiology 14:300–306PubMed
42.
go back to reference Hartung DM, Touchette DR, Bultemeier NC, Haxby DG (2005) Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a Medicaid claims-based case-control study. Pharmacotherapy 25:1329–1336PubMed Hartung DM, Touchette DR, Bultemeier NC, Haxby DG (2005) Risk of hospitalization for heart failure associated with thiazolidinedione therapy: a Medicaid claims-based case-control study. Pharmacotherapy 25:1329–1336PubMed
43.
go back to reference Johnsen SP, Monster TB, Olsen ML et al (2006) Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 13:134–140PubMed Johnsen SP, Monster TB, Olsen ML et al (2006) Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 13:134–140PubMed
44.
go back to reference Sauer WH, Cappola AR, Berlin JA, Kimmel SE (2006) Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol 97:651–654PubMed Sauer WH, Cappola AR, Berlin JA, Kimmel SE (2006) Insulin sensitizing pharmacotherapy for prevention of myocardial infarction in patients with diabetes mellitus. Am J Cardiol 97:651–654PubMed
45.
go back to reference Koro CE, Fu Q, Stender M (2008) An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Saf 17:989–996PubMed Koro CE, Fu Q, Stender M (2008) An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Saf 17:989–996PubMed
46.
go back to reference Dore DD, Trivedi AN, Mor V, Lapane KL (2009) Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. Pharmacotherapy 29:775–783PubMed Dore DD, Trivedi AN, Mor V, Lapane KL (2009) Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. Pharmacotherapy 29:775–783PubMed
47.
go back to reference Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM (2009) Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One 4:e6080PubMedPubMedCentral Dormuth CR, Maclure M, Carney G, Schneeweiss S, Bassett K, Wright JM (2009) Rosiglitazone and myocardial infarction in patients previously prescribed metformin. PLoS One 4:e6080PubMedPubMedCentral
48.
go back to reference MacDonald MR, Eurich DT, Majumdar SR et al (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 33:1213–1218PubMedPubMedCentral MacDonald MR, Eurich DT, Majumdar SR et al (2010) Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. Diabetes Care 33:1213–1218PubMedPubMedCentral
49.
go back to reference Azoulay L, Schneider-Lindner V, Dell'aniello S, Filion KB, Suissa S (2010) Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 19:343–350PubMed Azoulay L, Schneider-Lindner V, Dell'aniello S, Filion KB, Suissa S (2010) Thiazolidinediones and the risk of incident strokes in patients with type 2 diabetes: a nested case-control study. Pharmacoepidemiol Drug Saf 19:343–350PubMed
50.
go back to reference Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884PubMed Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884PubMed
51.
go back to reference Evans J, Ogston S, Emslie-Smith A, Morris A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936PubMed Evans J, Ogston S, Emslie-Smith A, Morris A (2006) Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin. Diabetologia 49:930–936PubMed
52.
go back to reference Kapinya K, Nijjar PS, Stanek M, Amanullah A (2008) Insulin-sensitizing antihyperglycaemic medications are associated with better outcome in patients with diabetes undergoing cardiac stress testing. Int Med J 38:259–264 Kapinya K, Nijjar PS, Stanek M, Amanullah A (2008) Insulin-sensitizing antihyperglycaemic medications are associated with better outcome in patients with diabetes undergoing cardiac stress testing. Int Med J 38:259–264
53.
go back to reference Pantalone KM, Kattan MW, Yu C et al (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46:145–154PubMed Pantalone KM, Kattan MW, Yu C et al (2009) The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol 46:145–154PubMed
54.
go back to reference Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800PubMed Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 95:1797–1800PubMed
55.
go back to reference Adami HO, McLaughlin J, Ekbom A et al (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307–314PubMed Adami HO, McLaughlin J, Ekbom A et al (1991) Cancer risk in patients with diabetes mellitus. Cancer Causes Control 2:307–314PubMed
56.
go back to reference Johnson E, Bartman B, Briesacher B et al (2013) The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 22:1–6PubMed Johnson E, Bartman B, Briesacher B et al (2013) The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 22:1–6PubMed
57.
go back to reference Ray W (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920PubMed Ray W (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158:915–920PubMed
58.
go back to reference McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM (2007) Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 16:711–725PubMed McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM (2007) Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 16:711–725PubMed
59.
go back to reference Walker AM, Koro CE, Landon J (2008) Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 17:760–768PubMed Walker AM, Koro CE, Landon J (2008) Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf 17:760–768PubMed
60.
go back to reference Winkelmayer WC, Setoguchi S, Levin R, Solomon DH (2008) Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 168:2368–2375PubMed Winkelmayer WC, Setoguchi S, Levin R, Solomon DH (2008) Comparison of cardiovascular outcomes in elderly patients with diabetes who initiated rosiglitazone vs pioglitazone therapy. Arch Intern Med 168:2368–2375PubMed
61.
go back to reference Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339:b2942PubMedPubMedCentral Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM (2009) Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 339:b2942PubMedPubMedCentral
62.
go back to reference Juhaeri J, Gao S, Dai WS (2009) Incidence rates of heart failure, stroke, and acute myocardial infarction among type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiol Drug Saf 18:497–503PubMed Juhaeri J, Gao S, Dai WS (2009) Incidence rates of heart failure, stroke, and acute myocardial infarction among type 2 diabetic patients using insulin glargine and other insulin. Pharmacoepidemiol Drug Saf 18:497–503PubMed
63.
go back to reference Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411–418PubMed Graham DJ, Ouellet-Hellstrom R, MaCurdy TE et al (2010) Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 304:411–418PubMed
64.
go back to reference Best JH, Hoogwerf BJ, Herman WH et al (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34:90–95PubMedPubMedCentral Best JH, Hoogwerf BJ, Herman WH et al (2011) Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 34:90–95PubMedPubMedCentral
65.
go back to reference Roumie CL, Hung AM, Greevy RA et al (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 157:601–610PubMed Roumie CL, Hung AM, Greevy RA et al (2012) Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med 157:601–610PubMed
66.
go back to reference Solomon DH, Glynn RJ, Rothman KJ et al (2008) Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 59:1097–1104PubMedPubMedCentral Solomon DH, Glynn RJ, Rothman KJ et al (2008) Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum 59:1097–1104PubMedPubMedCentral
67.
go back to reference Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ 87:1–406 Breslow NE, Day NE (1987) Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ 87:1–406
68.
go back to reference Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS (2003) Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 26:2983–2989PubMed Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS (2003) Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 26:2983–2989PubMed
69.
go back to reference Habib ZA, Tzogias L, Havstad SL et al (2009) Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 18:437–447PubMedPubMedCentral Habib ZA, Tzogias L, Havstad SL et al (2009) Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 18:437–447PubMedPubMedCentral
70.
go back to reference Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD (2007) The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 16:504–512PubMed Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD (2007) The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf 16:504–512PubMed
71.
go back to reference Andersson C, Gislason GH, Jorgensen CH et al (2011) Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract 94:119–125PubMed Andersson C, Gislason GH, Jorgensen CH et al (2011) Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure. Diabetes Res Clin Pract 94:119–125PubMed
72.
go back to reference Andersson C, Olesen JB, Hansen PR et al (2010) Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 53:2546–2553PubMed Andersson C, Olesen JB, Hansen PR et al (2010) Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: a retrospective nationwide cohort study. Diabetologia 53:2546–2553PubMed
73.
go back to reference Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM (2011) Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf 20:785–796PubMed Filion KB, Joseph L, Boivin JF, Suissa S, Brophy JM (2011) Thiazolidinediones and the risk of incident congestive heart failure among patients with type 2 diabetes mellitus. Pharmacoepidemiol Drug Saf 20:785–796PubMed
74.
go back to reference Hernan MA, Hernandez-Diaz S, Robins JM (2013) Randomized trials analyzed as observational studies. Ann Intern Med 159:560–562PubMed Hernan MA, Hernandez-Diaz S, Robins JM (2013) Randomized trials analyzed as observational studies. Ann Intern Med 159:560–562PubMed
75.
go back to reference Hernan M, Hernandez-Diaz S (2012) Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 9:48–55PubMedPubMedCentral Hernan M, Hernandez-Diaz S (2012) Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 9:48–55PubMedPubMedCentral
76.
go back to reference Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology, 3rd edn. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia Rothman KJ, Greenland S, Lash TL (2008) Modern epidemiology, 3rd edn. Wolters Kluwer Health/Lippincott Williams & Wilkins, Philadelphia
77.
go back to reference Jorgensen CH, Gislason GH, Andersson C et al (2010) Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention—a retrospective nationwide cohort study. Cardiovasc Diabetol 9:54PubMedPubMedCentral Jorgensen CH, Gislason GH, Andersson C et al (2010) Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention—a retrospective nationwide cohort study. Cardiovasc Diabetol 9:54PubMedPubMedCentral
78.
go back to reference Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900–1908PubMed Schramm TK, Gislason GH, Vaag A et al (2011) Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 32:1900–1908PubMed
79.
go back to reference Robins J (1992) Estimation of the time-dependent accelerated failure time model in the presence of confounding factors. Biometrika 79:321–334 Robins J (1992) Estimation of the time-dependent accelerated failure time model in the presence of confounding factors. Biometrika 79:321–334
80.
go back to reference Hernan M, Brumback B, Robins J (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11:561–570PubMed Hernan M, Brumback B, Robins J (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11:561–570PubMed
81.
go back to reference Robins J, Hernan M, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11:550–560PubMed Robins J, Hernan M, Brumback B (2000) Marginal structural models and causal inference in epidemiology. Epidemiology 11:550–560PubMed
82.
go back to reference Robins J (1986) A new approach to causal inference in mortality studies with sustained exposure periods—application to control of the healthy worker survivor effect. Math Model 7:1393–1512 Robins J (1986) A new approach to causal inference in mortality studies with sustained exposure periods—application to control of the healthy worker survivor effect. Math Model 7:1393–1512
83.
go back to reference Walker AM (1991) Observation and inference: an introduction to the methods of epidemiology. Epidemiology Resources Inc., Chestnut Hill Walker AM (1991) Observation and inference: an introduction to the methods of epidemiology. Epidemiology Resources Inc., Chestnut Hill
84.
go back to reference Walker AM (1996) Confounding by indication. Epidemiology 7:335–336PubMed Walker AM (1996) Confounding by indication. Epidemiology 7:335–336PubMed
85.
go back to reference Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577–581PubMed Petri H, Urquhart J (1991) Channeling bias in the interpretation of drug effects. Stat Med 10:577–581PubMed
86.
go back to reference Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta Centers for Disease Control and Prevention (2011) National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta
87.
go back to reference Berger AK, Breall JA, Gersh BJ et al (2001) Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). Am J Cardiol 87:272–277PubMed Berger AK, Breall JA, Gersh BJ et al (2001) Effect of diabetes mellitus and insulin use on survival after acute myocardial infarction in the elderly (the Cooperative Cardiovascular Project). Am J Cardiol 87:272–277PubMed
88.
go back to reference Smooke S, Horwich TB, Fonarow GC (2005) Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149:168–174PubMed Smooke S, Horwich TB, Fonarow GC (2005) Insulin-treated diabetes is associated with a marked increase in mortality in patients with advanced heart failure. Am Heart J 149:168–174PubMed
89.
go back to reference Aronow WS, Ahn C (2001) Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 88:556–557PubMed Aronow WS, Ahn C (2001) Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol 88:556–557PubMed
90.
go back to reference Fisman EZ, Tenenbaum A, Boyko V et al (2001) Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24:151–158PubMed Fisman EZ, Tenenbaum A, Boyko V et al (2001) Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24:151–158PubMed
91.
go back to reference Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583–590PubMed Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583–590PubMed
92.
go back to reference Arruda-Olson AM, Patch RK 3rd, Leibson CL et al (2009) Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 84:28–33PubMedPubMedCentral Arruda-Olson AM, Patch RK 3rd, Leibson CL et al (2009) Effect of second-generation sulfonylureas on survival in patients with diabetes mellitus after myocardial infarction. Mayo Clin Proc 84:28–33PubMedPubMedCentral
93.
go back to reference Monami M, Balzi D, Lamanna C et al (2007) Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 23:479–484PubMed Monami M, Balzi D, Lamanna C et al (2007) Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. Diabetes Metab Res Rev 23:479–484PubMed
94.
go back to reference Horsdal HT, Johnsen SP, Sondergaard F et al (2009) Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 25:515–522PubMed Horsdal HT, Johnsen SP, Sondergaard F et al (2009) Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study. Diabetes Metab Res Rev 25:515–522PubMed
95.
go back to reference Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731PubMedPubMedCentral Tzoulaki I, Molokhia M, Curcin V et al (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339:b4731PubMedPubMedCentral
96.
go back to reference Weih M, Amberger N, Wegener S, Dirnagl U, Reuter T, Einhaupl K (2001) Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke 32:2029–2032PubMed Weih M, Amberger N, Wegener S, Dirnagl U, Reuter T, Einhaupl K (2001) Sulfonylurea drugs do not influence initial stroke severity and in-hospital outcome in stroke patients with diabetes. Stroke 32:2029–2032PubMed
97.
go back to reference Inzucchi SE, Masoudi FA, Wang Y et al (2005) Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28:1680–1689PubMed Inzucchi SE, Masoudi FA, Wang Y et al (2005) Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 28:1680–1689PubMed
98.
go back to reference Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2643PubMed Lipscombe LL, Gomes T, Levesque LE, Hux JE, Juurlink DN, Alter DA (2007) Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298:2634–2643PubMed
99.
go back to reference Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L (2008) The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 29:166–176PubMed Mellbin LG, Malmberg K, Norhammar A, Wedel H, Ryden L (2008) The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial. Eur Heart J 29:166–176PubMed
100.
go back to reference Sadikot SM, Mogensen CE (2008) Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract 82:391–395PubMed Sadikot SM, Mogensen CE (2008) Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. Diabetes Res Clin Pract 82:391–395PubMed
101.
go back to reference Sillars B, Davis WA, Hirsch IB, Davis TM (2010) Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab 12:757–765PubMed Sillars B, Davis WA, Hirsch IB, Davis TM (2010) Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study. Diabetes Obes Metab 12:757–765PubMed
102.
go back to reference Stockl KM, Le L, Zhang S, Harada AS (2009) Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. Pharmacoepidemiol Drug Saf 18:166–174PubMed Stockl KM, Le L, Zhang S, Harada AS (2009) Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications. Pharmacoepidemiol Drug Saf 18:166–174PubMed
103.
go back to reference Ramirez SP, Albert JM, Blayney MJ et al (2009) Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol JASN 20:1094–1101 Ramirez SP, Albert JM, Blayney MJ et al (2009) Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol JASN 20:1094–1101
104.
go back to reference Vanasse A, Carpentier AC, Courteau J, Asghari S (2009) Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diab Vasc Dis Res 6:87–93PubMed Vanasse A, Carpentier AC, Courteau J, Asghari S (2009) Stroke and cardiovascular morbidity and mortality associated with rosiglitazone use in elderly diabetic patients. Diab Vasc Dis Res 6:87–93PubMed
105.
go back to reference Schneeweiss S, Patrick AR, Brookhart AM et al (2007) Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 45:S131–S142PubMedPubMedCentral Schneeweiss S, Patrick AR, Brookhart AM et al (2007) Increasing levels of restriction in pharmacoepidemiologic database studies of elderly and comparison with randomized trial results. Med Care 45:S131–S142PubMedPubMedCentral
106.
go back to reference Peduzzi PCJ, Kemper E, Holford TR, Feinstein AR (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49:1373–1379PubMed Peduzzi PCJ, Kemper E, Holford TR, Feinstein AR (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49:1373–1379PubMed
107.
go back to reference Cepeda MS, Boston R, Farrar JT, Strom BL (2003) Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 158:280–287PubMed Cepeda MS, Boston R, Farrar JT, Strom BL (2003) Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 158:280–287PubMed
108.
go back to reference Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55 Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55
109.
go back to reference D'Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281PubMed D'Agostino RB Jr (1998) Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265–2281PubMed
110.
go back to reference Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33–38 Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33–38
111.
go back to reference Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083–3107PubMedPubMedCentral Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083–3107PubMedPubMedCentral
112.
go back to reference Powers AC (2012) Diabetes mellitus. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J (eds) Harrison's principles of internal medicine, 18th edn. McGraw-Hill, New York Powers AC (2012) Diabetes mellitus. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson J, Loscalzo J (eds) Harrison's principles of internal medicine, 18th edn. McGraw-Hill, New York
113.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMed Inzucchi SE, Bergenstal RM, Buse JB et al (2012) Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 55:1577–1596PubMed
114.
go back to reference Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195PubMed Singh S, Loke YK, Furberg CD (2007) Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298:1189–1195PubMed
115.
go back to reference Nissen S, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMed Nissen S, Wolski K (2007) Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356:2457–2471PubMed
116.
go back to reference Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S (2011) Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 173:1404–1413PubMedPubMedCentral Rassen JA, Glynn RJ, Brookhart MA, Schneeweiss S (2011) Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 173:1404–1413PubMedPubMedCentral
117.
go back to reference Rassen JA, Schneeweiss S (2012) Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf 21:41–49PubMed Rassen JA, Schneeweiss S (2012) Using high-dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system. Pharmacoepidemiol Drug Saf 21:41–49PubMed
118.
go back to reference Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart AM (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20:512–522PubMedPubMedCentral Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart AM (2009) High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20:512–522PubMedPubMedCentral
119.
go back to reference Stergachis A (1988) Record linkage studies for postmarketing drug surveillance: data quality and validity considerations. Drug Intell Clin Pharmacol 22:157–161 Stergachis A (1988) Record linkage studies for postmarketing drug surveillance: data quality and validity considerations. Drug Intell Clin Pharmacol 22:157–161
120.
go back to reference McKenzie D, Semradek J, McFarland B, Mullooly J, McCamant L (2000) The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 53:1248–1257PubMed McKenzie D, Semradek J, McFarland B, Mullooly J, McCamant L (2000) The validity of medicaid pharmacy claims for estimating drug use among elderly nursing home residents: the Oregon experience. J Clin Epidemiol 53:1248–1257PubMed
121.
go back to reference West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142:1103–1112PubMed West SL, Savitz DA, Koch G, Strom BL, Guess HA, Hartzema A (1995) Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol 142:1103–1112PubMed
122.
go back to reference West SL, Strom BL, Freundlich B, Normand E, Koch G, Savitz DA (1994) Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol 47:165–171PubMed West SL, Strom BL, Freundlich B, Normand E, Koch G, Savitz DA (1994) Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol 47:165–171PubMed
123.
go back to reference Kelsey JL, Whittemore AS, Evans AS, Thompson W (1996) Methods in observational epidemiology. Monographs in epidemiology and biostatistics vol. 26, 2nd edn. Oxford University Press, New York, pp 341–361 Kelsey JL, Whittemore AS, Evans AS, Thompson W (1996) Methods in observational epidemiology. Monographs in epidemiology and biostatistics vol. 26, 2nd edn. Oxford University Press, New York, pp 341–361
124.
go back to reference Kiyota Y, Schneeweiss S, Glynn R, Cannuscio C, Avorn J, Solomon D (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148:99–104PubMed Kiyota Y, Schneeweiss S, Glynn R, Cannuscio C, Avorn J, Solomon D (2004) Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records. Am Heart J 148:99–104PubMed
125.
go back to reference Tirschwell D, Longstreth WJ (2002) Validating administrative data in stroke research. Stroke J Cereb Circ 33:2465–2470 Tirschwell D, Longstreth WJ (2002) Validating administrative data in stroke research. Stroke J Cereb Circ 33:2465–2470
126.
go back to reference Wahl P, Rodgers K, Schneeweiss S et al (2010) Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 19:596–603PubMed Wahl P, Rodgers K, Schneeweiss S et al (2010) Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population. Pharmacoepidemiol Drug Saf 19:596–603PubMed
127.
go back to reference Saczynski J, Andrade S, Harrold L et al (2012) A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 21:129–140PubMed Saczynski J, Andrade S, Harrold L et al (2012) A systematic review of validated methods for identifying heart failure using administrative data. Pharmacoepidemiol Drug Saf 21:129–140PubMed
128.
go back to reference Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF (2005) Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 43:480–485PubMed Birman-Deych E, Waterman AD, Yan Y, Nilasena DS, Radford MJ, Gage BF (2005) Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. Med Care 43:480–485PubMed
129.
go back to reference Hernandez-Diaz S, Adami HO (2010) Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 53:802–808PubMed Hernandez-Diaz S, Adami HO (2010) Diabetes therapy and cancer risk: causal effects and other plausible explanations. Diabetologia 53:802–808PubMed
130.
go back to reference Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665–2673PubMedPubMedCentral Suissa S, Azoulay L (2012) Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 35:2665–2673PubMedPubMedCentral
131.
go back to reference Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55:1607–1618PubMed Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55:1607–1618PubMed
132.
go back to reference Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55:1619–1632PubMed Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55:1619–1632PubMed
Metadata
Title
Observational studies of the association between glucose-lowering medications and cardiovascular outcomes: addressing methodological limitations
Authors
Elisabetta Patorno
Amanda R. Patrick
Elizabeth M. Garry
Sebastian Schneeweiss
Victoria G. Gillet
Dorothee B. Bartels
Elvira Masso-Gonzalez
John D. Seeger
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 11/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3364-z

Other articles of this Issue 11/2014

Diabetologia 11/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.